[Cost benefit of screening for type 1 diabetes. A futuristic scenario].

Article

[Cost benefit of screening for type 1 diabetes. A futuristic scenario].

Diabete & metabolisme - 1 Dec 1993

Lévy-Marchal C

Abstract excerpt

The current knowledge on prediction of Type 1 diabetes derives from family studies, as for example the BOX Study in England. Data indicate that first degree relatives with islet cells antibodies > or = 20 JDFu have a 35% risk to develop the disease within 5 years. But sensitivity and specificity...

Topics

Autoantibodies
Biomarkers
Cost-Benefit Analysis
Diabetes Mellitus, Type 1
France
Genotype
Humans
Islets of Langerhans
Mass Screening
Prevalence
Risk Factors
Sensitivity and Specificity

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.